Skip to main content
Top
Gepubliceerd in: Quality of Life Research 9/2015

01-09-2015

Association between single-nucleotide polymorphisms in growth factor genes and quality of life in men with prostate cancer and the general population

Auteurs: Kimberly E. Alexander, Suzanne Chambers, Amanda B. Spurdle, Jyotsna Batra, Felicity Lose, Tracy A. O’Mara, Robert A. Gardiner, Joanne F. Aitken, Judith A. Clements, Mary-Anne Kedda, Monika Janda

Gepubliceerd in: Quality of Life Research | Uitgave 9/2015

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

Improved survival for men with prostate cancer has led to increased attention to factors influencing quality of life (QOL). As protein levels of vascular endothelial growth factor (VEGF) and insulin-like growth factor 1 (IGF-1) have been reported to be associated with QOL in people with cancer, we sought to identify whether single-nucleotide polymorphisms (SNPs) of these genes were associated with QOL in men with prostate cancer.

Methods

Multiple linear regression of two data sets (including approximately 750 men newly diagnosed with prostate cancer and 550 men from the general population) was used to investigate SNPs of VEGF and IGF-1 (10 SNPs in total) for associations with QOL (measured by the SF-36v2 health survey).

Results

Men with prostate cancer who carried the minor ‘T’ allele for IGF-1 SNP rs35767 had higher mean Role-Physical scale scores (≥0.3 SD) compared to non-carriers (p < 0.05). While this association was not identified in men from the general population, one IGF-1 SNP rs7965399 was associated with higher mean Bodily Pain scale scores in men from the general population that was not found in men with prostate cancer. Men from the general population who carried the rare ‘C’ allele had higher mean Bodily Pain scale scores (≥0.3 SD) than non-carriers (p < 0.05).

Conclusions

Through identifying SNPs that are associated with QOL in men with prostate cancer and men from the general population, this study adds to the mapping of complex interrelationships that influence QOL and suggests a role for IGF-I in physical QOL outcomes. Future research may identify biomarkers associated with increased risk of poor QOL that could assist in the provision of pre-emptive support for those identified at risk.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
go back to reference Namiki, S., & Arai, Y. (2010). Health-related quality of life in men with localized prostate cancer. International Journal of Urology, 17(2), 125–138.PubMedCrossRef Namiki, S., & Arai, Y. (2010). Health-related quality of life in men with localized prostate cancer. International Journal of Urology, 17(2), 125–138.PubMedCrossRef
2.
go back to reference Romeis, J. C., Heath, A. C., Xian, H., Eisen, S. A., Scherrer, J. F., Pedersen, N. L., et al. (2005). Heritability of SF-36 among middle-age, middle-class, male–male twins. Medical Care, 43(11), 1147–1154.PubMedCrossRef Romeis, J. C., Heath, A. C., Xian, H., Eisen, S. A., Scherrer, J. F., Pedersen, N. L., et al. (2005). Heritability of SF-36 among middle-age, middle-class, male–male twins. Medical Care, 43(11), 1147–1154.PubMedCrossRef
3.
go back to reference Romeis, J. C., Scherrer, J. F., Xian, H., Eisen, S. A., Bucholz, K., Heath, A. C., et al. (2000). Heritability of self-reported health. Health Services Research, 35(5 Pt 1), 995–1010.PubMedCentralPubMed Romeis, J. C., Scherrer, J. F., Xian, H., Eisen, S. A., Bucholz, K., Heath, A. C., et al. (2000). Heritability of self-reported health. Health Services Research, 35(5 Pt 1), 995–1010.PubMedCentralPubMed
4.
go back to reference Nes, R. B., Roysamb, E., Tambs, K., Harris, J. R., & Reichborn-Kjennerud, T. (2006). Subjective well-being: Genetic and environmental contributions to stability and change. Psychological Medicine, 36(7), 1033–1042.PubMedCrossRef Nes, R. B., Roysamb, E., Tambs, K., Harris, J. R., & Reichborn-Kjennerud, T. (2006). Subjective well-being: Genetic and environmental contributions to stability and change. Psychological Medicine, 36(7), 1033–1042.PubMedCrossRef
5.
go back to reference Sprangers, M. A., Sloan, J. A., Veenhoven, R., Cleeland, C. S., Halyard, M. Y., Abertnethy, A. P., et al. (2009). The establishment of the GENEQOL consortium to investigate the genetic disposition of patient-reported quality-of-life outcomes. Twin Research and Human Genetics, 12(3), 301–311.PubMedCentralPubMedCrossRef Sprangers, M. A., Sloan, J. A., Veenhoven, R., Cleeland, C. S., Halyard, M. Y., Abertnethy, A. P., et al. (2009). The establishment of the GENEQOL consortium to investigate the genetic disposition of patient-reported quality-of-life outcomes. Twin Research and Human Genetics, 12(3), 301–311.PubMedCentralPubMedCrossRef
6.
go back to reference Sprangers, M. A., Sloan, J. A., Barsevick, A., Chauhan, C., Dueck, A. C., Raat, H., et al. (2010). Scientific imperatives, clinical implications, and theoretical underpinnings for the investigation of the relationship between genetic variables and patient-reported quality-of-life outcomes. Quality of Life Research, 19(10), 1395–1403.PubMedCentralPubMedCrossRef Sprangers, M. A., Sloan, J. A., Barsevick, A., Chauhan, C., Dueck, A. C., Raat, H., et al. (2010). Scientific imperatives, clinical implications, and theoretical underpinnings for the investigation of the relationship between genetic variables and patient-reported quality-of-life outcomes. Quality of Life Research, 19(10), 1395–1403.PubMedCentralPubMedCrossRef
7.
go back to reference Sprangers, M. A. G., Thong, M. S. Y., Bartels, M., Barsevick, A., Ordoñana, J., Shi, Q., et al. (2014). Biological pathways, candidate genes, and molecular markers associated with quality-of-life domains: An update. Quality of Life Research, 23(7), 1997–2013.PubMedCentralPubMedCrossRef Sprangers, M. A. G., Thong, M. S. Y., Bartels, M., Barsevick, A., Ordoñana, J., Shi, Q., et al. (2014). Biological pathways, candidate genes, and molecular markers associated with quality-of-life domains: An update. Quality of Life Research, 23(7), 1997–2013.PubMedCentralPubMedCrossRef
8.
9.
go back to reference Peters, C. A., Stock, R. G., Cesaretti, J. A., Atencio, D. P., Peters, S., Burri, R. J., et al. (2008). TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. International Journal of Radiation Oncology Biology Physics, 70(3), 752–759.CrossRef Peters, C. A., Stock, R. G., Cesaretti, J. A., Atencio, D. P., Peters, S., Burri, R. J., et al. (2008). TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. International Journal of Radiation Oncology Biology Physics, 70(3), 752–759.CrossRef
10.
go back to reference Langsenlehner, T., Renner, W., Gerger, A., Hofmann, G., Thurner, E. M., Kapp, K. S., et al. (2011). Impact of VEGF gene polymorphisms and haplotypes on radiation-induced late toxicity in prostate cancer patients. Strahlentherapie und Onkologie, 187(12), 784–791.PubMedCrossRef Langsenlehner, T., Renner, W., Gerger, A., Hofmann, G., Thurner, E. M., Kapp, K. S., et al. (2011). Impact of VEGF gene polymorphisms and haplotypes on radiation-induced late toxicity in prostate cancer patients. Strahlentherapie und Onkologie, 187(12), 784–791.PubMedCrossRef
11.
go back to reference De Langhe, S., De Ruyck, K., Ost, P., Fonteyne, V., Werbrouck, J., De Meerleer, G., et al. (2013). Acute radiation-induced nocturia in prostate cancer patients is associated with pretreatment symptoms, radical prostatectomy, and genetic markers in the TGFbeta1 gene. International Journal of Radiation Oncology Biology Physics, 85(2), 393–399.CrossRef De Langhe, S., De Ruyck, K., Ost, P., Fonteyne, V., Werbrouck, J., De Meerleer, G., et al. (2013). Acute radiation-induced nocturia in prostate cancer patients is associated with pretreatment symptoms, radical prostatectomy, and genetic markers in the TGFbeta1 gene. International Journal of Radiation Oncology Biology Physics, 85(2), 393–399.CrossRef
12.
go back to reference Langsenlehner, T., Thurner, E. M., Krenn-Pilko, S., Gerger, A., & Langsenlehner, U. (2012). Genetic prediction of radiation-induced morbidity in prostate cancer patients. Radiotherapy and Oncology, 105(3), 380–381.PubMedCrossRef Langsenlehner, T., Thurner, E. M., Krenn-Pilko, S., Gerger, A., & Langsenlehner, U. (2012). Genetic prediction of radiation-induced morbidity in prostate cancer patients. Radiotherapy and Oncology, 105(3), 380–381.PubMedCrossRef
13.
go back to reference Djavan, B., Waldert, M., Seitz, C., & Marberger, M. (2001). Insulin-like growth factors and prostate cancer. World Journal of Urology, 19(4), 225–233.PubMedCrossRef Djavan, B., Waldert, M., Seitz, C., & Marberger, M. (2001). Insulin-like growth factors and prostate cancer. World Journal of Urology, 19(4), 225–233.PubMedCrossRef
14.
go back to reference van Moorselaar, R. J., & Voest, E. E. (2002). Angiogenesis in prostate cancer: Its role in disease progression and possible therapeutic approaches. Molecular and Cellular Endocrinology, 197(1–2), 239–250.PubMedCrossRef van Moorselaar, R. J., & Voest, E. E. (2002). Angiogenesis in prostate cancer: Its role in disease progression and possible therapeutic approaches. Molecular and Cellular Endocrinology, 197(1–2), 239–250.PubMedCrossRef
15.
go back to reference Lutgendorf, S. K., Johnsen, E. L., Cooper, B., Anderson, B., Sorosky, J. I., Buller, R. E., et al. (2002). Vascular endothelial growth factor and social support in patients with ovarian carcinoma. Cancer, 95(4), 808–815.PubMedCrossRef Lutgendorf, S. K., Johnsen, E. L., Cooper, B., Anderson, B., Sorosky, J. I., Buller, R. E., et al. (2002). Vascular endothelial growth factor and social support in patients with ovarian carcinoma. Cancer, 95(4), 808–815.PubMedCrossRef
16.
go back to reference Meyerhardt, J. A., Sloan, J. A., Sargent, D. J., Goldberg, R. M., Pollak, M., Morton, R. F., et al. (2005). Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer. Cancer Epidemiology, Biomarkers and Prevention, 14(6), 1402–1410.PubMedCrossRef Meyerhardt, J. A., Sloan, J. A., Sargent, D. J., Goldberg, R. M., Pollak, M., Morton, R. F., et al. (2005). Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer. Cancer Epidemiology, Biomarkers and Prevention, 14(6), 1402–1410.PubMedCrossRef
17.
go back to reference Hinds, D. A., Stuve, L. L., Nilsen, G. B., Halperin, E., Eskin, E., Ballinger, D. G., et al. (2005). Whole-genome patterns of common DNA variation in three human populations. Science, 307(5712), 1072–1079.PubMedCrossRef Hinds, D. A., Stuve, L. L., Nilsen, G. B., Halperin, E., Eskin, E., Ballinger, D. G., et al. (2005). Whole-genome patterns of common DNA variation in three human populations. Science, 307(5712), 1072–1079.PubMedCrossRef
18.
go back to reference Baade, P. D., Aitken, J. F., Ferguson, M., Gardiner, R. A., & Chambers, S. K. (2010). Diagnostic and treatment pathways for men with prostate cancer in Queensland: Investigating spatial and demographic inequalities. BMC Cancer, 10, 452.PubMedCentralPubMedCrossRef Baade, P. D., Aitken, J. F., Ferguson, M., Gardiner, R. A., & Chambers, S. K. (2010). Diagnostic and treatment pathways for men with prostate cancer in Queensland: Investigating spatial and demographic inequalities. BMC Cancer, 10, 452.PubMedCentralPubMedCrossRef
19.
go back to reference Lose, F., Batra, J., O’Mara, T., Fahey, P., Marquart, L., Eeles, R. A., et al. (2013). Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness. Urologic Oncology, 31(5), 635–643.PubMedCrossRef Lose, F., Batra, J., O’Mara, T., Fahey, P., Marquart, L., Eeles, R. A., et al. (2013). Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness. Urologic Oncology, 31(5), 635–643.PubMedCrossRef
20.
go back to reference Batra, J., Lose, F., O’Mara, T., Marquart, L., Stephens, C., Alexander, K., et al. (2011). Association between Prostinogen (KLK15) genetic variants and prostate cancer risk and aggressiveness in Australia and a meta-analysis of GWAS data. PLoS ONE, 6(11), e26527.PubMedCentralPubMedCrossRef Batra, J., Lose, F., O’Mara, T., Marquart, L., Stephens, C., Alexander, K., et al. (2011). Association between Prostinogen (KLK15) genetic variants and prostate cancer risk and aggressiveness in Australia and a meta-analysis of GWAS data. PLoS ONE, 6(11), e26527.PubMedCentralPubMedCrossRef
21.
go back to reference Health Assessment Lab - Medical Outcomes Trust and QualityMetric Incorporated (2003). SF-36v2 Health Survey, IQOLA SF36v2 Standard, English (Australia). Health Assessment Lab - Medical Outcomes Trust and QualityMetric Incorporated (2003). SF-36v2 Health Survey, IQOLA SF36v2 Standard, English (Australia).
22.
go back to reference Fayers, P., & Machin, D. (2007). Quality of life: The Assessment, Analysis and Interpretation of Patient-reported Outcomes (Vol. Book, Whole): Wiley.CrossRef Fayers, P., & Machin, D. (2007). Quality of life: The Assessment, Analysis and Interpretation of Patient-reported Outcomes (Vol. Book, Whole): Wiley.CrossRef
23.
go back to reference Sommers, S. D., & Ramsey, S. D. (1999). A review of quality-of-life evaluations in prostate cancer. Pharmacoeconomics, 16(2), 127–140.PubMedCrossRef Sommers, S. D., & Ramsey, S. D. (1999). A review of quality-of-life evaluations in prostate cancer. Pharmacoeconomics, 16(2), 127–140.PubMedCrossRef
24.
go back to reference Hawthorne, G., Osborne, R. H., Taylor, A., & Sansoni, J. (2007). The SF36 Version 2: Critical analyses of population weights, scoring algorithms and population norms. Quality of Life Research, 16(4), 661–673.PubMedCrossRef Hawthorne, G., Osborne, R. H., Taylor, A., & Sansoni, J. (2007). The SF36 Version 2: Critical analyses of population weights, scoring algorithms and population norms. Quality of Life Research, 16(4), 661–673.PubMedCrossRef
25.
go back to reference Ware, J. E., Kosinski, M., Bjorner, J., Turner-Bowker, D., Gandek, B., & Maruish, M. (2007). User’s manual for the SF-36v2 health survey (2nd ed.). Lincoln: QualityMetric. Ware, J. E., Kosinski, M., Bjorner, J., Turner-Bowker, D., Gandek, B., & Maruish, M. (2007). User’s manual for the SF-36v2 health survey (2nd ed.). Lincoln: QualityMetric.
26.
go back to reference Lose, F., Nagle, C. M., O’Mara, T., Batra, J., Bolton, K. L., Song, H., et al. (2010). Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival. Gynecologic Oncolology, 119(3), 479–483.CrossRef Lose, F., Nagle, C. M., O’Mara, T., Batra, J., Bolton, K. L., Song, H., et al. (2010). Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival. Gynecologic Oncolology, 119(3), 479–483.CrossRef
27.
go back to reference Cheng, I., Stram, D. O., Penney, K. L., Pike, M., Le Marchand, L., Kolonel, L. N., et al. (2006). Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort. Journal of the National Cancer Institute, 98(2), 123–134.PubMedCrossRef Cheng, I., Stram, D. O., Penney, K. L., Pike, M., Le Marchand, L., Kolonel, L. N., et al. (2006). Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort. Journal of the National Cancer Institute, 98(2), 123–134.PubMedCrossRef
28.
go back to reference Rothman, K. J. (1990). No adjustments are needed for multiple comparisons. Epidemiology, 1(1), 43–46.PubMedCrossRef Rothman, K. J. (1990). No adjustments are needed for multiple comparisons. Epidemiology, 1(1), 43–46.PubMedCrossRef
29.
go back to reference Hattersley, A. T., & McCarthy, M. I. (2005). What makes a good genetic association study? Lancet, 366(9493), 1315–1323.PubMedCrossRef Hattersley, A. T., & McCarthy, M. I. (2005). What makes a good genetic association study? Lancet, 366(9493), 1315–1323.PubMedCrossRef
30.
go back to reference Edge, S. B., & American Joint Committee on, C. (2010). AJCC cancer staging manual (Vol. Book, Whole). New York: Springer. Edge, S. B., & American Joint Committee on, C. (2010). AJCC cancer staging manual (Vol. Book, Whole). New York: Springer.
31.
go back to reference Elis, S., Wu, Y., Courtland, H. W., Cannata, D., Sun, H., Beth-On, M., et al. (2011). Unbound (bioavailable) IGF1 enhances somatic growth. Disease Models and Mechanisms, 4(5), 649–658.PubMedCentralPubMedCrossRef Elis, S., Wu, Y., Courtland, H. W., Cannata, D., Sun, H., Beth-On, M., et al. (2011). Unbound (bioavailable) IGF1 enhances somatic growth. Disease Models and Mechanisms, 4(5), 649–658.PubMedCentralPubMedCrossRef
32.
go back to reference Palles, C., Johnson, N., Coupland, B., Taylor, C., Carvajal, J., Holly, J., et al. (2008). Identification of genetic variants that influence circulating IGF1 levels: A targeted search strategy. Human Molecular Genetics, 17(10), 1457–1464.PubMedCrossRef Palles, C., Johnson, N., Coupland, B., Taylor, C., Carvajal, J., Holly, J., et al. (2008). Identification of genetic variants that influence circulating IGF1 levels: A targeted search strategy. Human Molecular Genetics, 17(10), 1457–1464.PubMedCrossRef
33.
go back to reference Patel, A. V., Cheng, I., Canzian, F., Le Marchand, L., Thun, M. J., Berg, C. D., et al. (2008). IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: Findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS ONE, 3(7), e2578.PubMedCentralPubMedCrossRef Patel, A. V., Cheng, I., Canzian, F., Le Marchand, L., Thun, M. J., Berg, C. D., et al. (2008). IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: Findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS ONE, 3(7), e2578.PubMedCentralPubMedCrossRef
34.
go back to reference Kostek, M. C., Devaney, J. M., Gordish-Dressman, H., Harris, T. B., Thompson, P. D., Clarkson, P. M., et al. (2010). A polymorphism near IGF1 is associated with body composition and muscle function in women from the health, aging, and body composition study. European Journal of Applied Physiology, 110(2), 315–324.PubMedCentralPubMedCrossRef Kostek, M. C., Devaney, J. M., Gordish-Dressman, H., Harris, T. B., Thompson, P. D., Clarkson, P. M., et al. (2010). A polymorphism near IGF1 is associated with body composition and muscle function in women from the health, aging, and body composition study. European Journal of Applied Physiology, 110(2), 315–324.PubMedCentralPubMedCrossRef
35.
go back to reference Ben-Zaken, S., Meckel, Y., Nemet, D., & Eliakim, A. (2013). Can IGF-I polymorphism affect power and endurance athletic performance? Growth Hormone & IGF Research, 23(5), 175–178.CrossRef Ben-Zaken, S., Meckel, Y., Nemet, D., & Eliakim, A. (2013). Can IGF-I polymorphism affect power and endurance athletic performance? Growth Hormone & IGF Research, 23(5), 175–178.CrossRef
36.
go back to reference Qian, B., Zheng, H., Yu, H., & Chen, K. (2011). Genotypes and phenotypes of IGF-I and IGFBP-3 in breast tumors among Chinese women. Breast Cancer Research and Treatment, 130(1), 217–226.PubMedCrossRef Qian, B., Zheng, H., Yu, H., & Chen, K. (2011). Genotypes and phenotypes of IGF-I and IGFBP-3 in breast tumors among Chinese women. Breast Cancer Research and Treatment, 130(1), 217–226.PubMedCrossRef
37.
go back to reference Hernandez, W., Grenade, C., Santos, E. R., Bonilla, C., Ahaghotu, C., & Kittles, R. A. (2007). IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-Americans. Carcinogenesis, 28(10), 2154–2159.PubMedCrossRef Hernandez, W., Grenade, C., Santos, E. R., Bonilla, C., Ahaghotu, C., & Kittles, R. A. (2007). IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-Americans. Carcinogenesis, 28(10), 2154–2159.PubMedCrossRef
38.
go back to reference Cuatrecasas, G., Alegre, C., & Casanueva, F. F. (2014). GH/IGF1 axis disturbances in the fibromyalgia syndrome: Is there a rationale for GH treatment? Pituitary, 17(3), 277–283.PubMedCrossRef Cuatrecasas, G., Alegre, C., & Casanueva, F. F. (2014). GH/IGF1 axis disturbances in the fibromyalgia syndrome: Is there a rationale for GH treatment? Pituitary, 17(3), 277–283.PubMedCrossRef
39.
go back to reference Morgado, C., Silva, L., Pereira-Terra, P., & Tavares, I. (2011). Changes in serotoninergic and noradrenergic descending pain pathways during painful diabetic neuropathy: The preventive action of IGF1. Neurobiology of Disease, 43(1), 275–284.PubMedCrossRef Morgado, C., Silva, L., Pereira-Terra, P., & Tavares, I. (2011). Changes in serotoninergic and noradrenergic descending pain pathways during painful diabetic neuropathy: The preventive action of IGF1. Neurobiology of Disease, 43(1), 275–284.PubMedCrossRef
40.
go back to reference Miaskowski, C., Cooper, B. A., Melisko, M., Chen, L. M., Mastick, J., West, C., et al. (2014). Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy. Cancer, 120(15), 2371–2378.PubMedCentralPubMedCrossRef Miaskowski, C., Cooper, B. A., Melisko, M., Chen, L. M., Mastick, J., West, C., et al. (2014). Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy. Cancer, 120(15), 2371–2378.PubMedCentralPubMedCrossRef
41.
go back to reference Staff, I., Salner, A., Bohannon, R., Panatieri, P., & Maljanian, R. (2003). Disease-specific symptoms and general quality of life of patients with prostate carcinoma before and after primary three-dimensional conformal radiotherapy. Cancer, 98(11), 2335–2343.PubMedCrossRef Staff, I., Salner, A., Bohannon, R., Panatieri, P., & Maljanian, R. (2003). Disease-specific symptoms and general quality of life of patients with prostate carcinoma before and after primary three-dimensional conformal radiotherapy. Cancer, 98(11), 2335–2343.PubMedCrossRef
42.
go back to reference Clark, J. A., Rieker, P., Propert, K. J., & Talcott, J. A. (1999). Changes in quality of life following treatment for early prostate cancer. Urology, 53(1), 161–168.PubMedCrossRef Clark, J. A., Rieker, P., Propert, K. J., & Talcott, J. A. (1999). Changes in quality of life following treatment for early prostate cancer. Urology, 53(1), 161–168.PubMedCrossRef
43.
go back to reference Baumeister, H., Kriston, L., Bengel, J., & Harter, M. (2010). High agreement of self-report and physician-diagnosed somatic conditions yields limited bias in examining mental-physical comorbidity. Journal of Clinical Epidemiology, 63(5), 558–565.PubMedCrossRef Baumeister, H., Kriston, L., Bengel, J., & Harter, M. (2010). High agreement of self-report and physician-diagnosed somatic conditions yields limited bias in examining mental-physical comorbidity. Journal of Clinical Epidemiology, 63(5), 558–565.PubMedCrossRef
44.
go back to reference Schwartz, C. E., & Sprangers, M. A. (1999). Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research. Social Science and Medicine, 48(11), 1531–1548.PubMedCrossRef Schwartz, C. E., & Sprangers, M. A. (1999). Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research. Social Science and Medicine, 48(11), 1531–1548.PubMedCrossRef
45.
go back to reference Korfage, I. J., Hak, T., de Koning, H. J., & Essink-Bot, M. L. (2006). Patients’ perceptions of the side-effects of prostate cancer treatment—a qualitative interview study. Social Science and Medicine, 63(4), 911–919.PubMedCrossRef Korfage, I. J., Hak, T., de Koning, H. J., & Essink-Bot, M. L. (2006). Patients’ perceptions of the side-effects of prostate cancer treatment—a qualitative interview study. Social Science and Medicine, 63(4), 911–919.PubMedCrossRef
Metagegevens
Titel
Association between single-nucleotide polymorphisms in growth factor genes and quality of life in men with prostate cancer and the general population
Auteurs
Kimberly E. Alexander
Suzanne Chambers
Amanda B. Spurdle
Jyotsna Batra
Felicity Lose
Tracy A. O’Mara
Robert A. Gardiner
Joanne F. Aitken
Judith A. Clements
Mary-Anne Kedda
Monika Janda
Publicatiedatum
01-09-2015
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 9/2015
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-015-0950-6

Andere artikelen Uitgave 9/2015

Quality of Life Research 9/2015 Naar de uitgave